Trial Profile
A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Levomilnacipran (Primary) ; Quetiapine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 18 Jun 2018 Status changed from recruiting to completed.
- 09 May 2017 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.
- 09 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2018.